Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sanofi ADR is a drug manufacturers-general business based in the US. Sanofi ADR shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi ADR employs 95,442 staff and has a trailing 12-month revenue of around $44.3 billion.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $48.49 |
|---|---|
| 52-week range | $36.91 - $56.08 |
| 50-day moving average | $46.98 |
| 200-day moving average | $47.15 |
| Wall St. target price | $64.00 |
| PE ratio | 17.6679 |
| Dividend yield | $3.33 (3.59%) |
| Earnings per share (TTM) | $2.77 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $48.49 from 2023-01-27
| 1 week (2023-01-23) | -0.29% |
|---|---|
| 1 month (2022-12-30) | 0.12% |
| 3 months (2022-10-31) | 12.17% |
| 6 months (2022-07-29) | -2.43% |
| 1 year (2022-01-31) | -6.75% |
|---|---|
| 2 years (2021-01-29) | 2.71% |
| 3 years (2020-01-31) | 0.46% |
| 5 years (2018-01-30) | 8.21% |
Valuing Sanofi ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Sanofi ADR shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6501. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.2 billion.
The EBITDA is a measure of a Sanofi ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $44.3 billion |
|---|---|
| Operating margin TTM | 23.98% |
| Gross profit TTM | $26.9 billion |
| Return on assets TTM | 4.91% |
| Return on equity TTM | 10% |
| Profit margin | 14.45% |
| Book value | $28.34 |
| Market capitalisation | $123.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 48.2% of net profits
Recently Sanofi ADR has paid out, on average, around 48.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi ADR shareholders could enjoy a 3.59% return on their shares, in the form of dividend payments. In Sanofi ADR's case, that would currently equate to about $3.33 per share.
While Sanofi ADR's payout ratio might seem fairly standard, it's worth remembering that Sanofi ADR may be investing much of the rest of its net profits in future growth.
Sanofi ADR's most recent dividend payout was on 26 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 25 May 2022 (the "ex-dividend date").
Sanofi ADR's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi ADR shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi ADR shares which in turn could have impacted Sanofi ADR's share price.
Over the last 12 months, Sanofi ADR's shares have ranged in value from as little as $36.91 up to $56.0802. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi ADR's is 0.4349. This would suggest that Sanofi ADR's shares are less volatile than average (for this exchange).
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
